Dashboard
Manage Tickers

VERA


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

cantor-fitzgerald-reiterates-overweight-on-vera-therapeutics-maintains-107-price-target
Cantor Fitzgerald Reiterates Overweight on...
09/16/2024 17:05:58

Cantor Fitzgerald analyst Pete Stavropoulos reiterates Vera Therapeutics (NASDAQ:VERA) with a Overweight and maintains $107 ...

vera-therapeutics-to-host-in-person-rd-day-to-discuss-potential-indication-expansion-for-atacicept-on-october-2-2024
Vera Therapeutics To Host In-Person R&D Da...
09/16/2024 12:06:17

Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing tr...

vera-therapeutics-completes-enrollment-for-primary-endpoint-in-pivotal-phase-3-origin-3-trial-of-atacicept-in-igan
Vera Therapeutics Completes Enrollment For...
09/12/2024 12:01:29

On track to announce topline results from ORIGIN 3 trial in Q2 2025 Expect to present 96-week data from ORIGIN Phase 2b clinica...

cantor-fitzgerald-reiterates-overweight-on-vera-therapeutics-maintains-107-price-target
Cantor Fitzgerald Reiterates Overweight on...
09/09/2024 16:17:38

Cantor Fitzgerald analyst Pete Stavropoulos reiterates Vera Therapeutics (NASDAQ:VERA) with a Overweight and maintains $107 ...

cantor-fitzgerald-reiterates-overweight-on-vera-therapeutics-maintains-107-price-target
Cantor Fitzgerald Reiterates Overweight on...
09/06/2024 13:52:55

Cantor Fitzgerald analyst Pete Stavropoulos reiterates Vera Therapeutics (NASDAQ:VERA) with a Overweight and maintains $107 ...

vaxcyte-shoals-technologies-polestar-automotive-applied-optoelectronics-and-other-big-stocks-moving-higher-on-tuesday
Vaxcyte, Shoals Technologies, Polestar Aut...
09/03/2024 14:47:56

jp-morgan-maintains-overweight-on-vera-therapeutics-raises-price-target-to-72
JP Morgan Maintains Overweight on Vera The...
09/03/2024 13:54:40

JP Morgan analyst Anupam Rama maintains Vera Therapeutics (NASDAQ:VERA) with a Overweight and raises the price target from $...

jp-morgan-maintains-overweight-on-vera-therapeutics-lowers-price-target-to-62
JP Morgan Maintains Overweight on Vera The...
08/13/2024 12:39:25

JP Morgan analyst Anupam Rama maintains Vera Therapeutics (NASDAQ:VERA) with a Overweight and lowers the price target from $...

vera-therapeutics-q2-eps-062-misses-056-estimate
Vera Therapeutics Q2 EPS $(0.62) Misses $(...
08/08/2024 12:46:02

Vera Therapeutics (NASDAQ:VERA) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $...

vera-therapeutics-appoints-david-johnson-as-coo
Vera Therapeutics Appoints David Johnson A...
07/01/2024 12:09:01

stericycle-marinemax-agios-pharmaceuticals-and-other-big-stocks-moving-higher-on-monday
Stericycle, MarineMax, Agios Pharmaceutica...
06/03/2024 14:39:44

wall-street-snaps-five-week-winning-streak-economic-growth-slows-inflation-holds-steady-in-april-this-week-in-the-market
Wall Street Snaps Five-Week Winning Streak...
05/31/2024 20:15:22

U.S. stock market ends 5-week positive streak due to slowing economic momentum, while Nvidia's valuation soars and home pri...

jp-morgan-maintains-overweight-on-vera-therapeutics-raises-price-target-to-65
JP Morgan Maintains Overweight on Vera The...
05/31/2024 17:20:26

JP Morgan analyst Anupam Rama maintains Vera Therapeutics (NASDAQ:VERA) with a Overweight and raises the price target from $...

nvidia-is-up-186-from-a-year-ago-yet-these-7-stocks-have-more-than-doubled-their-returns-over-the-ai-chipmaker
Nvidia Is Up 186% From A Year Ago, Yet The...
05/29/2024 21:56:11

NVIDIA Corp. (NASDAQ:NVDA) has been the standout tech stock of the past year, leading the Nasdaq 100 index in the performance r...

vera-therapeutics-receives-fda-breakthrough-therapy-designation-for-atacicept-in-igan
Vera Therapeutics Receives FDA Breakthroug...
05/28/2024 12:05:29

reported-saturday-vera-therapeutics-presented-72-week-egfr-stabilization-and-rapid-hematuria-improvement-in-phase-2b-origin-study-of-atacicept-in-igan-at-the-61st-european-renal-association-congress
Reported Saturday, Vera Therapeutics Prese...
05/28/2024 07:38:12

72-week data consistent with disease modification in IgAN, selected as a best-ranked abstract; Rapid and sustained improveme...

raymond-james-maintains-strong-buy-on-vera-therapeutics-raises-price-target-to-68
Raymond James Maintains Strong Buy on Vera...
05/10/2024 17:10:32

Raymond James analyst Steven Seedhouse maintains Vera Therapeutics (NASDAQ:VERA) with a Strong Buy and raises the price targ...

update--vera-therapeutics-q1-eps-056-up-from-080-yoy
UPDATE: Vera Therapeutics Q1 EPS $(0.56) ...
05/09/2024 12:59:01

Vera Therapeutics (NASDAQ:VERA) reported quarterly losses of $(0.56) per share. This is a 30 percent increase over losses of $(...

vertexs-alpine-acquisition-unpacking-analyst-predictions-on-povetacicepts-potential-impact
Vertex's Alpine Acquisition: Unpacking Ana...
04/11/2024 18:47:33

Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion, expanding into nephrology with promising APOL1-media...

why-rallybio-shares-are-trading-higher-by-around-78-here-are-20-stocks-moving-premarket
Why Rallybio Shares Are Trading Higher By ...
04/11/2024 10:14:41

Shares of Rallybio Corporation (NASDAQ: RLYB) rose sharply in today’s pre-market trading after the company announced a collabo...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION